Squaric acid dibutyl ester - Squarex

Drug Profile

Squaric acid dibutyl ester - Squarex

Alternative Names: SADBE

Latest Information Update: 16 Dec 2016

Price : $50

At a glance

  • Originator Squarex
  • Class Immunotherapies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Herpes labialis

Most Recent Events

  • 16 Dec 2016 Phase-I/II clinical trials in Herpes labialis (Prevention, Recurrent) in USA (Topical) (NCT02965781)
  • 24 Oct 2016 Squarex plans a phase I/II trial in Herpes labialis (Prevention, Recurrent) in USA (NCT02965781)
  • 01 Apr 2016 Preclinical trials in Herpes labialis (Prevention, Recurrent) in USA (Topical)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top